Tolerx

Results: 4



#Item
1For internal review only: Draft as of March 23, 2015 Lycera Announces Milestone in Merck Collaboration NEW YORK and ANN ARBOR, Mich., Mar. 25, Lycera Corp., a biopharmaceutical company developing breakthrough me

For internal review only: Draft as of March 23, 2015 Lycera Announces Milestone in Merck Collaboration NEW YORK and ANN ARBOR, Mich., Mar. 25, Lycera Corp., a biopharmaceutical company developing breakthrough me

Add to Reading List

Source URL: www.edfvc.com

Language: English - Date: 2015-03-31 10:51:59
2Lycera Expands Leadership Team, Names H. Jeffrey Wilkins, M.D., as Chief Medical Officer - Dr. Wilkins to lead advancement of Lycera’s clinical programs, including first clinical trial anticipated to begin in 2Q 2015 N

Lycera Expands Leadership Team, Names H. Jeffrey Wilkins, M.D., as Chief Medical Officer - Dr. Wilkins to lead advancement of Lycera’s clinical programs, including first clinical trial anticipated to begin in 2Q 2015 N

Add to Reading List

Source URL: www.edfvc.com

Language: English - Date: 2015-03-11 10:40:38
3Microsoft Word - IMMUNOMEDICS AWARDED DOD GRANT FOR MILATUZUMAB IN LUPUS.doc

Microsoft Word - IMMUNOMEDICS AWARDED DOD GRANT FOR MILATUZUMAB IN LUPUS.doc

Add to Reading List

Source URL: www.immunomedics.com

Language: English - Date: 2013-09-30 13:12:42
4Editorial For reprint orders, please contact [removed] EBV infection and anti-CD3 treatment for Type 1 diabetes: bad cop, good cop? Expert Rev. Clin. Immunol. 9(2), 95–[removed])

Editorial For reprint orders, please contact [removed] EBV infection and anti-CD3 treatment for Type 1 diabetes: bad cop, good cop? Expert Rev. Clin. Immunol. 9(2), 95–[removed])

Add to Reading List

Source URL: www.faustmanlab.org

Language: English - Date: 2013-12-11 22:21:47